Nuvaxovid Covid-19 Vaccine, Adjuvanted
Product Images NDC 80631-207

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Nuvaxovid Covid-19 Vaccine, Adjuvanted (NDC 80631-207). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novavax, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Nuvaxovid 2024-2025 Formula (Carton)

Carton packaging label for NUVAXOVID COVID-19 Vaccine, Adjuvanted, 2024-2025 Formula by Novavax, Inc. The label states it is a COVID-19 vaccine for intramuscular use, intended for 65 years and older and for people 12 through 64 years at high risk for severe COVID-19. The package contains 10 single-dose pre-filled syringes, each with 0.5 mL dose. Storage instructions specify refrigeration between 2°C and 8°C and no freezing.*

FDA Label Image

Nuvaxovid 2024-2025 Formula (Syringe Label)

Label panel for NUVAXOVID COVID-19 Vaccine, Adjuvanted by Novavax, Inc., indicating the 2024-2025 formula. Features a barcode with GTIN and space for lot number and expiration date, along with a data matrix code containing GTIN, lot, and expiry information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.